Clinical Trials Browser

Phase 2 × Triiodothyronine × 90 days × Clear all

NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Phase 2 Active not recruiting

Ependymoma, Medulloblastoma